Stigmatization and perceived health status in patients with hidradenitis suppurativa: an observational multicenter study in Europe
Servando E. Marron,Tamara Gracia‐Cazaña,Francesca Sampogna,Christina Schut,Joerg Kupfer,Florence J. Dalgard,Anthony Bewley,Sylvia van Beugen,Uwe Gieler,Lars Lien,Sonja Ständer,Nienke Vulink,Andrew Y. Finlay,Franz J. Legat,Geraldine Titeca,Gregor B. Jemec,Laurent Misery,Csanad Szabo,Vesna Grivcheva‐Panovska,Saskia Spillekom‐van Koulil,Flora Balieva,Jacek C. Szepietowski,Adam Reich,Bárbara Roque Ferreira,Andrey Lvov,Dmitry Romanov,Ake Svensson,Ilknur K. Altunay,Andrew R. Thompson,Claudia Zeidler,Lucía Tomas‐Aragones,the ESDAP Study Collaborators
DOI: https://doi.org/10.1111/ijd.17569
2024-11-13
International Journal of Dermatology
Abstract:Illustration showing the clinical variables and PSQ scale associated with the stigmatization of Hidradenitis Suppurativa (HS). Introduction Hidradenitis suppurativa (HS) can severely affect the quality of life (QoL) and is linked to psychological distress, including anxiety, depression, and reduced self‐esteem. Stigmatization due to physical appearance may significantly contribute to the psychological burden and impact on QoL for HS patients. This study investigates the association between stigmatization, depression, anxiety, and health‐ and disease‐related variables among HS patients in Europe. Patients and methods This observational cross‐sectional multicenter study was conducted across 22 dermatological outpatient clinics in 17 European countries. Data collected included sociodemographic variables, general health variables, disease‐related variables, perceived stigmatization (PSQ), and mental health (PHQ‐2, GAD‐2). Results Of the 5487 dermatological patients, 142 (2.6%) were diagnosed with HS, and data from 135 patients (70.1% women, mean age 38.2 years) who completed the PSQ questionnaire were analyzed. Scores on the stigmatization measure indicated that significant stigmatization levels were present in the sample. Linear regression models revealed a significant relationship between stigmatization and both the duration of HS and the presence of itch. Similar findings were noted for the PSQ "confused/staring behavior" scale with depression. The PSQ "absence of friendly behavior" scale was inversely associated with general health status, whereas the "hostile behavior" scale was positively linked to depression. Conclusion HS patients experience significant stigmatization linked to disease duration, itch, and depression. Comprehensive management, including screening for psychosocial co‐morbidity, is essential, as is providing access to psychological interventions that support patients to both manage internal distress and the potential reactions of others.
dermatology